Hospice Quality Score Assessment Post Pharmacist Intervention

September 1, 2022 updated by: Tabula Rasa HealthCare

Assessing the Impact of Pharmacist Interventions on Hospice Quality Scores

The study aims to investigate the impact of pharmacist delivered interventions on hospice patients quality metric scores.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

The objective of this study is evaluate a program at a hospice involving activities designed to improve the site's National Quality Forum (NQF) and Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores. These scores are calculated by the hospice using existing patient satisfaction survey scores (HCAHPS). The institution quantifies their compliance with national quality metrics (NQF) and reports this existing data to the pharmacist providing counseling services to their patients. The pharmacist assesses for areas for improvement and provides additional counseling services to improve the continuity and quality of care. The pilot program is scheduled to launch April 2020 and the researchers will look to assess for changes in the NQF scores, HCAHPS scores, and time for their partnering pharmacy to refill the first set of prescriptions.

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Tucson, Arizona, United States, 85701
        • Tabula Rasa HealthCare

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 88 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Study population will be hospice population who received services for 6-months (e.g., between April 2020 to October 2020) and information including: age (excluding patients 89 years or older), gender, medication risk score, NQF score, HCAHPS score, time to fill medication order set, type of chronic condition, and number of medications will be studied.

Description

Inclusion Criteria:

Adult patients who were referred to hospice by a healthcare provider

Exclusion Criteria:

Patients 89 years or older

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Intervention
Patients that receive pharmacist-delivered services in the pilot program
Other: Medication safety review
Implementation of a medication safety review using a clinical decision support system
Control
Patients that do not receive pharmacist-delivered services in the pilot program
Other: Medication safety review
Implementation of a medication safety review using a clinical decision support system

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
National Quality Forum Score
Time Frame: 6 months
Performance metric used by hospice. Scale 0 - 100 (0=min; 100-high)
6 months
Consumer Assessment of Healthcare Providers and Systems
Time Frame: 6 months
Performance metric used by hospice (0=min; 100-high)
6 months
Time to refill
Time Frame: 6 months
Time to refill prescription from hospice organization (0=min; 100-high)
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tabula Rasa HealthCare

Investigators

  • Principal Investigator: Jennifer Bingham, PharmD, Tabula Rasa HealthCare

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 22, 2020

Primary Completion (Anticipated)

September 1, 2022

Study Completion (Actual)

September 1, 2022

Study Registration Dates

First Submitted

April 22, 2020

First Submitted That Met QC Criteria

April 22, 2020

First Posted (Actual)

April 24, 2020

Study Record Updates

Last Update Posted (Actual)

September 7, 2022

Last Update Submitted That Met QC Criteria

September 1, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TRHC_RD_Hospice_2020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on Medication safety review

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe